Literature DB >> 30473166

Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients; A systematic review and meta-analysis.

Seong-Jang Kim1, Kyoungjune Pak2, Keunyoung Kim2.   

Abstract

OBJECTIVE: The purpose of the current study was to investigate the diagnostic performance of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) for the detection of cervical lymph node (LN) metastasis in clinically node negative head and neck squamous cell cancer (cN0 HNSCC) patients through a systematic review and meta-analysis.
METHODS: The PubMed and EMBASE database, from the earliest available date of indexing through April 30, 2018, were searched for studies evaluating the diagnostic performance of F-18 FDG PET or PET/CT for the detection of LN metastasis in cN0 HNSCC patients. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic (SROC) curves.
RESULTS: Across 18 studies (1044 patients), the pooled sensitivity for F-18 FDG PET or PET/CT for the detection of LN metastasis was 0.58 and a pooled specificity of 0.87 for patient based analysis. Neck side based analysis showed the pooled sensitivity of 0.67 and a pooled specificity of 0.85. Level based study demonstrated the pooled sensitivity of 0.53 and a pooled specificity of 0.97 (95% CI; 0.95-0.98). In meta-regression analysis, no definite variable was the source of the study heterogeneity.
CONCLUSION: The current meta-analysis showed the low sensitivity and moderate specificity of F-18 FDG PET/CT for the detection of cervical LN metastasis in cN0 HNSCC patients. Level based analysis of F-18 FDG PET or PET/CT has a high specificity and NPV for the detection of cervical metastatic LN detection.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  F-18 FDG; Lymph node; PET; PET/CT: Head and neck cancer

Mesh:

Substances:

Year:  2018        PMID: 30473166     DOI: 10.1016/j.amjoto.2018.10.013

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  5 in total

1.  18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer.

Authors:  Mi Rye Bae; Jong-Lyel Roh; Jae Seung Kim; Jeong Hyun Lee; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-12       Impact factor: 4.553

Review 2.  Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Authors:  George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

3.  Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer.

Authors:  Heiko Schöder; Paula Demétrio De Souza França; Reiko Nakajima; Eva Burnazi; Sheryl Roberts; Christian Brand; Milan Grkovski; Audrey Mauguen; Mark P Dunphy; Ronald A Ghossein; Serge K Lyashchenko; Jason S Lewis; Joseph A O'Donoghue; Ian Ganly; Snehal G Patel; Nancy Y Lee; Thomas Reiner
Journal:  Clin Cancer Res       Date:  2020-04-03       Impact factor: 12.531

4.  Predictive Value of Occult Metastasis and Survival Significance of Metabolic Tumor Volume Determined by PET-CT in cT1-2N0 Squamous Cell Carcinoma of the Tongue.

Authors:  Lijie Yang; Fei Liu; Yao Wu; Qigen Fang; Xiaojun Zhang; Wei Du; Xu Zhang; Defeng Chen; Ruihua Luo
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

5.  ADC Values of Cytologically Benign and Cytologically Malignant 18 F-FDG PET-Positive Lymph Nodes of Head and Neck Squamous Cell Carcinoma.

Authors:  Petra K de Koekkoek-Doll; Sander Roberti; Laura Smit; Wouter V Vogel; Regina Beets-Tan; Michiel W van den Brekel; Jonas Castelijns
Journal:  Cancers (Basel)       Date:  2022-08-20       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.